Eligibility Screening
The rigor of screening before a GLP-1 is prescribed — BMI criteria, contraindications, and the specific risk checks the drugs require.
Why it matters
GLP-1s carry real contraindications, including a thyroid-cancer boxed warning. A provider that skips serious screening to convert more sign-ups is trading your safety for its funnel.
How we assess it
We check whether the screening matches the drug’s known risks.
- Stated BMI and eligibility criteria
- Contraindication questions
- Thyroid / MEN2 and other drug-specific risk screening
Source types: The provider’s intake and eligibility criteria and the questions its screening actually asks.
How we score it
Thorough, criteria-based screening scores high. A form that approves nearly everyone with no meaningful contraindication check is the red flag and scores low.
- Importance
- High
High — a heavily weighted tier within GLP-1, because screening is a front-line safety control.
- Scope
- Weight Management / GLP-1 overlay
What this tier is worth
Not medical advice
- Scope
- Weight Management / GLP-1 overlay
How this shows up in real reviews
Cited evidence we captured on this factor in live provider reviews.
- SkinnyRx
SkinnyRx publishes its screening process on its own site: a pre-qualification medical intake, then "a licensed clinician will review your information", then - "based on your health needs and state-specific requirements" - either a video visit or a prescription within 24 hours. Its product pages state that "licensed clinicians review your medical history, current medications, and risk factors to determine whether treatment is appropriate". Pregnancy and breastfeeding are named as a contraindication in two places, the FAQ and the injection guide ("Semaglutide should not be used during pregnancy or breastfeeding"). Eligibility is re-checked at every monthly refill, and the patient is not charged if found ineligible. The published patient protocols carry an "Indications and Contraindications" section. Confirmed on the rendered page 2026-08-23. CONFIRMED ABSENT ON THE RENDERED PAGE, not merel
- Gala Health
The screening criteria are published before signup, which is uncommon in this category. Gala's semaglutide and tirzepatide pages both state a BMI of 27 or above with a weight-related condition, or 30 or above without one — the FDA-labelled indication — and both publish the labelled semaglutide and tirzepatide contraindications: medullary thyroid cancer, multiple endocrine neoplasia type 2 and pancreatitis.